Key result
TMEM43 disruption in zebrafish causes progressive cardiac enlargement, ultrastructural remodeling, and transcriptomic defects.
Why the study?
Arrhythmogenic cardiomyopathy is caused by mutations in TMEM43, but the role of TMEM43 in the pathogenesis remains poorly understood.
This zebrafish preclinical model provides evidence that TMEM43 abnormalities lead to structural cardiac defects via ultrastructural remodeling and transcriptomic alterations.
TMEM43 variants drive cardiac defects in zebrafish; hypothesis-generating for arrhythmogenic cardiomyopathy mechanisms and requires human validation before clinical relevance.
Arrhythmogenic cardiomyopathy (ACM) is an inherited heart muscle disease caused by heterozygous missense mutations within the gene encoding for the nuclear envelope protein transmembrane protein 43 (TMEM43). The disease is characterized by myocyte loss and fibro-fatty replacement, leading to life-threatening ventricular arrhythmias and sudden cardiac death. However, the role of TMEM43 in the pathogenesis of ACM remains poorly understood. In this study, we generated cardiomyocyte-restricted transgenic zebrafish lines that overexpress eGFP-linked full-length human wild-type (WT) TMEM43 and two genetic variants (c.1073C>T, p.S358L; c.332C>T, p.P111L) using the Tol2-system. Overexpression of WT and p.P111L-mutant TMEM43 was associated with transcriptional activation of the mTOR pathway and ribosome biogenesis, and resulted in enlarged hearts with cardiomyocyte hypertrophy. Intriguingly, mutant p.S358L TMEM43 was found to be unstable and partially redistributed into the cytoplasm in embryonic and adult hearts. Moreover, both TMEM43 variants displayed cardiac morphological defects at juvenile stages and ultrastructural changes within the myocardium, accompanied by dysregulated gene expression profiles in adulthood. Finally, CRISPR/Cas9 mutants demonstrated an age-dependent cardiac phenotype characterized by heart enlargement in adulthood. In conclusion, our findings suggest ultrastructural remodeling and transcriptomic alterations underlying the development of structural and functional cardiac defects in TMEM43-associated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Zink et al. (2022) studied Arrhythmogenic cardiomyopathy. TMEM43 genetic manipulation (overexpression of WT/mutants and CRISPR/Cas9 knockout) vs. Non-transgenic (NTG) controls was evaluated on Cardiac morphological defects and transcriptomic alterations. Transgenic overexpression of TMEM43 variants and CRISPR/Cas9 loss-of-function in zebrafish resulted in ultrastructural remodeling, transcriptomic alterations, and cardiac morphological defects such as age-dependent heart enlargement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: